Tenofovir alafenamide
- Generic Name
- Tenofovir alafenamide
- Brand Names
- Biktarvy, Descovy, Genvoya, Odefsey, Vemlidy
- Drug Type
- Small Molecule
- Chemical Formula
- C21H29N6O5P
- CAS Number
- 379270-37-8
- Unique Ingredient Identifier
- EL9943AG5J
- Background
Tenofovir alafenamide is a novel tenofovir prodrug developed in order to improve renal safety when compared to the counterpart tenofovir disoproxil. Both of these prodrugs were first created to cover the polar phosphonic acid group on tenofovir by using a novel oxycarbonyloxymethyl linkers to improve the oral bioavailability and intestinal diffusion. Tenofov...
- Indication
Tenofovir alafenamide is indicated for the treatment of hepatitis B virus infection in adults and pediatric patients 12 years of age and older with compensated liver disease.
...
- Associated Conditions
- Chronic Hepatitis B Infection, Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- Pre-Exposure Prophylaxis (PrEP)
The Effectiveness and Safety of Tenofovir Alafenamide in the Treatment of Chronic Hepatitis B Patients With Mildly Elevated Alanine Aminotransferase and Significant Liver Injury.
- First Posted Date
- 2020-12-19
- Last Posted Date
- 2020-12-22
- Lead Sponsor
- National Cheng-Kung University Hospital
- Target Recruit Count
- 40
- Registration Number
- NCT04674423
- Locations
- 🇨🇳
National Cheng-Kung University Hospital, Tainan, Taiwan
TAF to Prevent HBV Reactivation in Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2020-11-06
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Chiayi Christian Hospital
- Target Recruit Count
- 102
- Registration Number
- NCT04619082
- Locations
- 🇨🇳
Dalin Tzu Chi General Hospital, Chiayi City, Taiwan
🇨🇳Ditmanson Medical Foundation Chiayi Christian Hospital, Chiayi City, Taiwan
🇨🇳St. Martin De Porress Hospital, Chiayi City, Taiwan
A Study of JNJ-73763989, Pegylated Interferon Alpha-2a, Nucleos(t)Ide Analog (NA) With or Without JNJ-56136379 in Treatment-naive Participants With Hepatitis B e Antigen (HBeAg) Positive Chronic Hepatitis B Virus (HBV) Infection
- Conditions
- Interventions
- First Posted Date
- 2020-06-19
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 54
- Registration Number
- NCT04439539
- Locations
- 🇬🇧
Kings College Hospital, London, United Kingdom
🇬🇧Grahame Hayton Unit, London, United Kingdom
🇺🇸Ruane Clinical Research Group Inc, Los Angeles, California, United States
Three Types of Nucleotide/Nucleoside Analogues Therapy in Patients With Hepatitis b Virus Related Compensated Cirrhosis
- Conditions
- Interventions
- First Posted Date
- 2019-12-12
- Last Posted Date
- 2019-12-12
- Target Recruit Count
- 150
- Registration Number
- NCT04196998
- Locations
- 🇨🇳
Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Three Types of Nucleotide/Nucleoside Analogues Therapy in Patients With Chronic Hepatitis b
- Conditions
- Interventions
- First Posted Date
- 2019-12-11
- Last Posted Date
- 2019-12-17
- Target Recruit Count
- 300
- Registration Number
- NCT04195074
- Locations
- 🇨🇳
Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Tenofovir Alafenamide With Fine Needle Aspiration Biopsy in Chronic Hepatitis B:
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 15
- Registration Number
- NCT04070079
- Locations
- 🇨🇦
Toronto General Hospital, Toronto, Ontario, Canada
Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B
- Conditions
- Interventions
- First Posted Date
- 2019-05-01
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Taichung Veterans General Hospital
- Target Recruit Count
- 420
- Registration Number
- NCT03933384
- Locations
- 🇨🇳
Taichung Veterans General Hospital, Taichung, Taiwan
Three Types of Nucleotide/Nucleoside Analogues Treatment in HBV Related ACLF
- Conditions
- Interventions
- First Posted Date
- 2019-04-19
- Last Posted Date
- 2024-11-28
- Target Recruit Count
- 150
- Registration Number
- NCT03920618
- Locations
- 🇨🇳
Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Prophylactic Antiviral Therapy in Patients With Current or Past Hepatitis B Virus Infection Receiving Anti-Cancer Therapy for Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2019-03-25
- Last Posted Date
- 2024-05-20
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 4
- Registration Number
- NCT03887702
- Locations
- 🇺🇸
Prisma Health Cancer Institute - Easley, Easley, South Carolina, United States
🇺🇸M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸Health Partners Inc, Minneapolis, Minnesota, United States
The Incidence of Hepatitis B in Diffuse Large B-Cell Lymphoma/Chronic Lymphoid Leukemia HBsAg-positive Treated With Rituximab, Chemotherapy and Tenofovir Alafenamide
- Conditions
- Interventions
- First Posted Date
- 2019-01-15
- Last Posted Date
- 2024-10-22
- Target Recruit Count
- 5
- Registration Number
- NCT03804372
- Locations
- 🇮🇹
Università degli Studi "Sapienza" - Dip Biotecnologie Cellulari ed Ematologia - Divisione di Ematologia, Roma, (rm), Italy
🇮🇹Aon Ss. Antonio E Biagio E C. Arrigo - Alessandria - Soc Ematologia, Alessandria, Italy
🇮🇹Aou Ospedali Riuniti "Umberto I - G.M. Lancisi - G. Salesi"- Ancona - Sod Clinica Ematologica, Ancona, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.